-
1Academic Journal
Συγγραφείς: M. S. Mendibaev, S. E. Rabotinsky, М. С. Мендибаев, С. Е. Работинский
Πηγή: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 20, № 1 (2023); 81-88 ; Вестник анестезиологии и реаниматологии; Том 20, № 1 (2023); 81-88 ; 2541-8653 ; 2078-5658
Θεματικοί όροι: экстракорпоральный контур, thromboelastogram, heparin resistance, anticoagulation, extracorporeal circuit, тромбоэластограмма, гепаринорезистентность, антикоагуляция
Περιγραφή αρχείου: application/pdf
Relation: https://www.vair-journal.com/jour/article/view/758/613; Строков А. Г., Поз Я. Л. Антикоагуляция при заместительной почечной терапии: классические подходы и новые возможности // Вестн. трансплантологии и искусственных органов. – 2010. – Т. 12, № 4. – С. 80–85.; Akil A., Ziegeler S., Reichelt J. et al. Use of CytoSorb and ECMO in patients with severe pneumogenic sepsis // Thorac Cardiovasc Surg. – 2021. – Vol. 69, № 3. – P. 246–251. Doi:10.1055/s-0040-1708479.; Arepally G. M., Ortel T. L. Heparin-induced thrombocytopenia // Annu Rev Med. – 2010. – Vol. 61. – P. 77–90. Doi:10.1146/annurev.med.042808.171814.; Bai M., Zhou M., He L. et al. Citrate versus heparin anticoagulationfor continuous renal replacement therapy: an updated meta-analysis of RCTs // Intensive Care Med. – 2015. – Vol. 41, № 12. – P. 2098–110. Doi:10.1007/s00134-015-4099-0.; Baldwin I., Tan H. K., Bridge N. et al. A prospective study of thromboelastography (TEG) and filter life during continuous veno-venous hemofiltration // Ren Fail. – 2000. – Vol. 22, № 3. – P. 297–306. Doi:10.1081/jdi-100100873.; Brouwer W. P., Duran S., Kuijper M. et al. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study // Crit Care. – 2019. – Vol. 23, № 1. – P. 317. Doi:10.1186/s13054-019-2588-1.; Brunner R., Madl C., Druml W. et al. Single-dose application of antithrombin III as alternative anticoagulation during extracorporeal therapy in critically ill patients with advanced liver cirrhosis: a retrospective data analysis // Crit Care. – 2011. – Vol. 15 (Suppl 1). – P. 123. Doi:10.1186/cc9543.; Cruz D.N., Antonelli M., Fumagalli R. et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial // JAMA. – 2009. – Vol. 301, № 23. – P. 2445–2452. Doi:10.1001/jama.2009.856.; Davenport A., Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit // NDT Plus. – 2009. – Vol. 6. – P. 439–447. Doi:10.1093/ndtplus/sfp136.; Davenport A. What are the anticoagulation options for intermittent hemodialysis? // Nat Rev Nephrol. – 2011. – Vol. 7, № 9. – P. 499–508. Doi:10.1038/nrneph.2011.88.; Dellinger R. P., Bagshaw S. M., Antonelli M. et al. EUPHRATES trial investigators. Effect of targeted polymyxin b hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial // JAMA. – 2018. – Vol. 320, № 14. – P. 1455–1463. Doi:10.1001/jama.2018.14618.; du Cheyron D., Bouchet B., Bruel C. et al. Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study // Crit Care. – 2006. – Vol. 10, № 2. – R45. Doi:10.1186/cc4853.; Eller T., Busse J., Dittrich M. et al. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests // Clin Chem Lab Med. – 2014. – Vol. 52, № 6. – P. 835–844. Doi:10.1515/cclm-2013-0936.; Gonano C., Sitzwohl C., Meitner E. et al. Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis // Crit Care. – 2006. – Vol. 10, № 6. – P. R160. Doi:10.1186/cc5098.; Honore P. M., De Bels D., Redant S. et al. Inducible metabolic pathway for citrate metabolism in case of major liver dysfunction: fact or fiction? // Crit Care. – 2019. – Vol. 23, № 1. – P. 166. Doi:10.1186/s13054-019-2432-7.; James M. F., Roche A. M. Dose-response relationship between plasma ionized calcium concentration and thrombelastography // J Cardiothorac Vasc Anesth. – 2004. – Vol. 18, 5. – P. 581–586. Doi:10.1053/j.jvca.2004.07.016.; Joannidis M., Kountchev J., Rauchenzauner M. et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study // Intensive Care Med. – 2007. – Vol. 33, № 9. – P. 1571–1579. Doi:10.1007/s00134-007-0719-7.; Kawazoe Y., Sato T., Miyagawa N. et al. Mortality effects of prolonged hemoperfusion therapy using a polymyxin b-immobilized fiber column for patients with septic shock: a sub-analysis of the DESIRE trial // Blood Purif. – 2018. – Vol. 46, № 4. – P. 309–314. Doi:10.1159/000491744.; Kellum J. A., Lameire N. KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1) // Crit Care. – 2013. – Vol. 17, № 1. – P. 204. Doi:10.1186/cc11454.; Khadzhynov D., Dahlinger A., Schelter C. et al. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation // Crit Care Med. – 2017. – Vol. 45 , № 9. – P. e941–e946. Doi:10.1097/CCM.0000000000002501.; Khadzhynov D., Schelter C., Lieker I. et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation // J Crit Care. – 2014. – Vol. 29, № 2. – P. 265–271. Doi:10.1016/j.jcrc.2013.10.015.; Klingele M., Stadler T., Fliser D. et al. Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction // Crit Care. – 2017. – Vol. 21, № 1. – P. 294. Doi:10.1186/s13054-017-1870-3.; Kogelmann K., Hübner T., Schwameis F. et al. First Evaluation of a New Dynamic Scoring System Intended to Support Prescription of adjuvant cytosorb hemoadsorption therapy in patients with septic shock // J Clin Med. – 2021. – Vol. 10, № 13. – P. 2939. Doi:10.3390/jcm10132939.; Lazrak H. H., René É., Elftouh N. et al. Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis // BMC Nephrol. – 2017. – Vol. 18, № 1. – P. 187. Doi:10.1186/s12882-017-0596-4.; Lee C. T., Chao A., Lai C. H. et al. Heparin dosing score protocol for anticoagulation during polymyxin B hemoperfusion // J Formos Med Assoc. – 2018. – Vol. 117, № 7. – P. 652–653. Doi:10.1016/j.jfma.2018.03.001.; Legrand M., Tolwani A. Anticoagulation strategies in continuous renal replacement therapy // Semin Dial. – 2021. – Vol. 34, № 6. – P. 416–422. Doi:10.1111/sdi.12959.; Levi M., Meijers J. C. DIC: which laboratory tests are most useful // Blood Rev. – 2011. – Vol. 25, № 1. – P. 33–37. Doi:10.1016/j.blre.2010.09.002.; Li X., Liu C., Mao Z. et al. Effectiveness of polymyxin B-immobilized hemoperfusion against sepsis and septic shock: A systematic review and meta-analysis // J Crit Care. – 2021. – Vol. 63. – P. 187–195. Doi:10.1016/j.jcrc.2020.09.007.; Li Z., Wang G., Zhen G. et al. Effects of hemodialysis combined with hemoperfusion on severe acute pancreatitis // Turk J Gastroenterol. – 2018. – Vol. 29, № 2. – P. 198–202. Doi:10.5152/tjg.2018.17415.; Lim W., Cook D. J., Crowther M. A. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials // J Am Soc Nephrol. – 2004. – Vol. 15, № 12. – P. 3192–3206. Doi:10.1097/01.ASN.0000145014.80714.35.; Liu C., Mao Z., Kang H. et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials // Crit Care. – 2016. – Vol. 20, № 1. – P. 144. Doi:10.1186/s13054-016-1299-0.; Mahieu E., Claes K., Jacquemin M. et al. Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation // Artif Organs. – 2013. – Vol. 37, № 5. – P. 482–487. Doi:10.1111/aor.12002.; Maurin N. Heparin resistance and antithrombin deficiency // Med Klin (Munich). – 2009. – Vol. 104, № 6. – P. 441–449. Doi:10.1007/s00063-009-1093-8.; Oudemans-van Straaten H. M., Kellum J. A., Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy-heparin or citrate? // Crit Care. – 2011. – Vol. 15, № 1. – P. 202. Doi:10.1186/cc9358.; Panicucci F., Sagripanti A., Conte B. et al. Antithrombin III, heparin cofactor and antifactor Xa in relation to age, sex and pathological condition // Haemostasis. – 1980. – Vol. 9, № 5. – P. 297–302. Doi:10.1159/000214368. PMID: 7409613.; Payen D. M., Guilhot J., Launey Y. et al. ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial // Intensive Care Med. – 2015. – Vol. 41, № 6. – P. 975–984. Doi:10.1007/s00134-015-3751-z.; Ricci Z., Romagnoli S. Technical complications of continuous renal replacement therapy // Сontrib Тephrol. – 2018. – Vol. 194. – P. 99–108. Doi:10.1159/000485607.; Rugg C., Klose R., Hornung R. et al. Hemoadsorption with Cytosorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective ‘genetic’ matched analysis // Biomedicines. – 2020. – Vol. 28, № 12. – P. 539. Doi:10.3390/biomedicines8120539.; Santoshi R. K., Patel R., Patel N. S. et al. Comprehensive review of thrombocytopenia with a spotlight on intensive care patients // Cureus. – 2022. – Vol. 14, № 8. – e27718. Doi:10.7759/cureus.27718.; Hoppensteadt D., Walenga J. M., Fareed J. et al. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation // Hematol Oncol Clin North Am. – 2003. – Vol. 17, № 1. – P. 313–341. Doi:10.1016/s0889-8588(02)00091-6.; Schetz M. Anticoagulation in continuous renal replacement therapy // Contrib Nephrol. – 2001. – Vol. 132. – P. 283–303. Doi:10.1159/000060097.; Schilder L., Nurmohamed S. A., Bosch F. H. et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial // Crit Care. – 2014. – Vol. 18, № 4. – P. 472. Doi:10.1186/s13054-014-0472-6.; Schneider A. G., Journois D., Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload? // Crit Care. – 2017. – Vol. 21, № 1. – P. 281. Doi:10.1186/s13054-017-1880-1.; Schultheiß C., Saugel B., Phillip V. et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study // Crit Care. – 2012. – Vol. 16, № 4. – R162. Doi:10.1186/cc11485. PMID: 22913794; PMCID: PMC3580752.; Schwarzer P., Kuhn S.O., Stracke S. et al. Discrepant post filter ionized calcium concentrations by common blood gas analyzers in CRRT using regional citrate anticoagulation // Crit Care. – 2015. – Vol. 19, № 1. – P. 321. Doi:10.1186/s13054-015-1027-1.; Slowinski T., Morgera S., Joannidis M. et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study // Crit Care. – 2015. – Vol. 19. – P. 349. Doi:10.1186/s13054-015-1066-7.; Vincent J. L., Laterre P. F., Cohen J. et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection // Shock. – 2005. – Vol. 23, № 5. – P. 400-405. Doi:10.1097/01.shk.0000159930.87737.8a.; White D., MacDonald S., Bull T. et al. Heparin resistance in COVID-19 patients in the intensive care unit // J Thromb Thrombolysis. – 2020. – Vol. 50, № 2. – P. 287–291. Doi:10.1007/s11239-020-02145-0.; Young E., Podor T. J., Venner T. et al. Induction of the acute-phase reaction increases heparin-binding proteins in plasma // Arterioscler Thromb Vasc Biol. – 1997. – Vol. 17, № 8. – P. 1568–1574. Doi:10.1161/01.atv.17.8.1568.; Zhang W., Bai M., Yu Y. et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis // Crit Care. – 2019. – Vol. 23, № 1. – P. 22. Doi:10.1186/s13054-019-2317-9.